Black Diamond Therapeutics (BDTX) Research & Development (2019 - 2026)

Black Diamond Therapeutics (BDTX) has reported Research & Development for 8 consecutive years, with $7.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 20.67% year-over-year to $7.4 million; the trailing twelve-month figure through Jun 2026 stood at $28.1 million (down 37.54% YoY), and the FY2025 full-year result was $33.6 million, down 34.6% from the prior year.
• Research & Development rose to $7.4 million in Q2 2026 per BDTX's latest filing, from $7.0 million in the prior quarter.
• Across five years, Research & Development topped out at $17.8 million in Q1 2022 and bottomed at $6.3 million in Q4 2025.
• Historically, Research & Development has averaged $12.4 million across 5 years, with a median of $13.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Research & Development increased 4.65% in 2023, then slumped 48.8% in 2025.
• Over 5 years, Research & Development stood at $14.6 million in 2022, then climbed by 4.65% to $15.3 million in 2023, then dropped by 19.57% to $12.3 million in 2024, then plunged by 48.8% to $6.3 million in 2025, then climbed by 17.42% to $7.4 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $7.4 million, $7.0 million, and $6.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.